We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Agentic AI Platform Supports Genomic Decision-Making in Oncology

By LabMedica International staff writers
Posted on 01 Jun 2026

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. More...

Translating multimodal data into patient-specific, point-of-care guidance remains difficult within routine clinical workflows. To address this gap, a newly upgraded physician platform now embeds next-generation agentic artificial intelligence (AI) to proactively surface genomic insights and generate patient-ready documentation, aiming to streamline decision support in oncology care.

Tempus AI (Chicago, IL, USA) has upgraded its AI-enabled smart physician platform, Tempus Hub, by embedding a next-generation generative AI clinical co-pilot that delivers an agent-first experience for healthcare providers. The upgrade connects the company’s advanced agentic AI directly with real-time patient data within Hub, aligning large language model capabilities with each patient’s diagnostic results to support cancer care decisions. Hub is a secure platform used by thousands of oncologists and care teams to deliver actionable insights at the point of care.

Within Hub, clinicians can access Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient. The new architecture adds proactive, agentic AI that can automatically produce patient overviews and apply deeper analysis to a patient’s Tempus genomic results on the summary page. It also expands into next-step documentation generation, enabling instant creation of patient-specific materials such as prior authorizations and patient messages by pulling directly from Tempus data.

These capabilities are supported by foundational connectivity layers: Edge, which enables real-time connections to electronic health record (EHR) systems and other provider platforms; Locker, which allows providers to store data in a secure, provider‑controlled environment; and Air, which deploys AI models and algorithms in real time at the point of care. Planned iterations include linking Tempus genomics results with the company’s longitudinal patient registry or health information exchange (HIE) data to enable more complex generative AI workflows. Together, these additions are intended to scale how providers utilize, interpret, and act on complex diagnostic insights during routine encounters.

“Our evolution toward an agent-first experience within the Tempus Hub represents a massive win for clinical workflow efficiency,” said Shane Colley, Chief Technology Officer at Tempus. “By bringing our most sophisticated co-pilot intelligence directly into the Hub, we are unlocking the true power of multimodal data to provide seamless, on-demand decision support that meets providers exactly where they are."

Related Links
Tempus AI


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.